A randomized, placebo-controlled, double-blind phase 1/2 trial evaluating the tolerability, pharmacokinetics, pharmacodynamics and efficacy of subcutaneous MET-097

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

01 Oct 2024 New trial record
24 Sep 2024 According to a Metsera media release, the company has announced positive topline results from the Phase 1 clinical trial of MET-097, achieving significant and durable weight loss and supporting a potential once-monthly dosing regimen. MET-097, incorporated Metsera's HALO platform technology, and achieved 380-hour half-life

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com